Navigation Links
Tiny genetic variation can predict ovarian cancer outcome
Date:12/5/2011

Yale Cancer Center researchers have shown that a tiny genetic variation predicts chances of survival and response to treatment for patients with ovarian cancer.

The findings, published in the journal Oncogene, provide new insights into the biology of a new class of cancer marker and suggest a genetic test may help guide the treatment of women with ovarian cancer.

"This gives us a way to identify which women are at highest risk for resistance to platinum chemotherapy, the standard treatment for ovarian cancer, and helps identify ovarian cancer patients with the worst outcomes," said Joanne Weidhaas, associate professor of therapeutic radiology and senior author of the study. "There just aren't many inherited gene variants than can do that."

Women who possess the biomarker identified by the Yale team a variant of the well-known KRAS oncogene are three times more resistant to standard platinum chemotherapy than women without the variant. Also, post-menopausal women with the variant are significantly more likely to die from ovarian cancer. About 12-15 percent of Caucasians and 6 percent of African-Americans are born with the variant of the gene, which helps regulate destruction of damaged cells. This variant is found in up to 25% of newly diagnosed ovarian cancer patients.

Although good alternatives to chemotherapy are not yet available for women with ovarian cancer and this variant, several drugs in development which target the KRAS gene and associated pathways have shown great promise, Weidhaas said.

Weidhaas is a co-founder of a company that has licensed intellectual property from Yale that has developed a diagnostic test based on the Kras-variant.

The biomarker intrigues scientists because it is a functional variant in an area of DNA that does not code for proteins. Instead this variant disrupts how a microRNA controls gene expression.

"This is a new paradigm," Weidhaas said.

Yale
'/>"/>

Contact: Bill Hathaway
william.hathaway@yale.edu
203-432-1322
Yale University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Genetic sequencing could help match patients with biomarker-driven cancer trials, treatments
2. Unlocking the genetic and molecular mystery of soft-tissue sarcoma
3. CU-Boulder led study of smoking twins points to growing influence of genetic factors
4. Increasing dosage of clopidogrel for patients with genetic variation improves response to medication
5. Combination epigenetic therapy clinical trial results
6. Epigenetic therapy shows promise in hard-to-treat lung cancer
7. Breakthrough in understanding the genetics of high blood pressure
8. Possible Genetic Link to Autism Identified
9. Ohio State researchers design a viral vector to treat a genetic form of blindness
10. Study identifies genetic basis of human metabolic individuality
11. 23andMe discovers genetic variant that may protect those at risk for Parkinsons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 Definitive Healthcare ... and healthcare providers, is pleased to announce the ... online database, now available for subscription, features detailed ... health system affiliations. , The Canadian database spans ... intelligence on over 750 hospitals. Each hospital ...
(Date:9/16/2014)... An experimental positron emission tomography (PET) ... a person is still alive, according to a case ... Mount Sinai, and at Molecular Neuroimaging (MNI) LLC in ... Translational Psychiatry. , Specifically, the study results suggest that ... designed to latch onto a protein called tau that ...
(Date:9/16/2014)... Terminsurancevirginia.com has released a new blog ... life insurance for obese clients. , Obese clients ... quotes. It is unlikely for applicants to be denied ... life insurance costs. , Having life insurance is ... Life insurance is available as temporary or permanent coverage ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Gary F. ... of China, has selected Worldwide Speakers Group for exclusive ... U.S. Secretary of Commerce and Governor of Washington, Locke ... authorities on U.S.-China relations, global expansion, and business growth. ... global competitiveness and how to grow an organization’s global ...
(Date:9/16/2014)... 2014 Representatives with safetyBUILT-IN ( ... the first phase of a safety-culture-development initiative for ... York, and just recently launched Phase II of ... now the third such facility where safetyBUILT-IN has ... safetyBUILT-IN Principal Eric Svendsen, Ph.D. “The first two ...
Breaking Medicine News(10 mins):Health News:Canadian Hospital Database Now Offered by Definitive Healthcare 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 3Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 4Health News:Obese Clients Can Find Affordable No Exam Term Life Insurance at Terminsurancevirginia.com! 2Health News:Gary Locke, Former Ambassador to China, Selects Worldwide Speakers Group for Exclusive Lecture Representation 2Health News:safetyBUILT-IN Leads Safety-Culture Field-Coaching Effort 2
... a virtually eradicated disease that eats through people's skin, ... South America. ,WHO reported that it ... the skin and bone wasting disease Yaws. The disease ... a bacterial infection, can cause debilitating deformations, particularly in ...
... local and international experts, vaulting over a buffer between ... Central province, for the first time. This has created ... Nairobi. ,The buffer was created by the ... Organisation (WHO) and Food and Agricultural Organisation (FAO). ...
... risk of catching bird flu, as the deadly virus is most ... on cats in areas where outbreaks have occurred found that the ... the chilling prospect that the disease could soon easily be spread ... shows that should bird flu ever break out in Britain, cat ...
... predict disease outbreaks may want to tune into more weather ... finding out when an epidemic is imminent because they determine ... ,The techniques can help quicken the response to ... heat wave and global warming is adding urgency to such ...
... of Informatics-led team of researchers has constructed a model ... across the globe// by airliners. ,The study, ... and Containment Intervention," appears in the January issue of ... said to be the world's largest-scale epidemic simulation of ...
... A new study suggests that TEMPE, a topical anesthetic ... treatment for men with premature ejaculation and might be ... study is published in the February issue of the ... UK and Netherlands studied 54 men with premature ejaculation, ...
Cached Medicine News:Health News:Kenya: Alert As Virus Leaps Over Buffer Zone 2Health News:Kenya: Alert As Virus Leaps Over Buffer Zone 3Health News:Cat Owners at Risk of Bird Flu 2Health News:Experts Use Weather to Predict Disease 2Health News:Scientists Assess Risk of Flu Pandemic Spread Via Global Airlines 2Health News:Scientists Assess Risk of Flu Pandemic Spread Via Global Airlines 3Health News:TEMPE Spray Delays Ejaculation 2
(Date:9/16/2014)... Sept. 16, 2014  DNAtrix, Inc., experts in ... patient was treated with the company,s lead product, ... in a randomized, multicenter, open-label Phase Ib study ... in collaboration with leading neurosurgeons and neuro-oncologists in ... of our randomized Phase Ib study of DNX-2401 ...
(Date:9/16/2014)... 2014  Eli Lilly and Company (NYSE: ... agreement to co-develop and commercialize AZD3293, an oral ... development as a potential treatment for Alzheimer,s disease. ... characterized by the accumulation of amyloid plaque in ... the development of beta-amyloid. Inhibiting BACE is expected ...
(Date:9/15/2014)... WHIPPANY, N.J. , Sept. 16, 2014 /PRNewswire/ ... based in Espoo, Finland , ... III trial with ODM-201, an investigational oral androgen ... ARAMIS, evaluates ODM-201 in men with castration-resistant prostate ... levels and no detectable metastases. The trial is ...
Breaking Medicine Technology:DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3
... and KOS, Greece, June 29, 2007 /PRNewswire/ --,The ... treated patients on REVLIMID (lenalidomide) plus the,steroid dexamethasone ... The data are pooled from two large randomized,controlled ... patients,from nearly 100 clinical sites worldwide. These updated ...
... at the 11th International Myeloma Workshop ... of perifosine in,combination with bortezomib, dexamethasone ... relapsed/refractory multiple,myeloma, and as a single ... NEW YORK, June 29, 2007 /PRNewswire-FirstCall/ ...
Cached Medicine Technology:The European Myeloma Platform Reports New Survival data for,Revlimid Presented at the International Myeloma Workshop in Greece 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: